Evidence map›Paper›PMID 27882219›Full record

ArticleBiomedical reports2016

CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence.

Mariella De Ameida Melo, Rodrigo José De Vasconcelos-Valença, Fidelis Manes Neto, Rafael Soares Borges, Danylo Rafhael Costa-Silva, Maria Da Conceição Barros-Oliveira, Umbelina Soares Borges, Airlane Pereira Alencar, Vladimir Costa Silva, Benedito Borges Da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Pooled it
  2. Review
  3. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Journal of cancer research and clinical oncology · 2020
    Review
  4. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariella De Ameida MeloDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil; Department of Oncology, São Marcos Hospital, Teresina, PI 64001-280, Brazil.
Rodrigo José De Vasconcelos-ValençaDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil; Department of Oncology, São Marcos Hospital, Teresina, PI 64001-280, Brazil.
Fidelis Manes NetoDepartment of Oncology, São Marcos Hospital, Teresina, PI 64001-280, Brazil.
Rafael Soares BorgesDepartment of Mastology, Getulio Vargas Hospital, Federal University of Piauí, Teresina, PI 64001-020, Brazil.
Danylo Rafhael Costa-SilvaDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil.
Maria Da Conceição Barros-OliveiraDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil.
Umbelina Soares BorgesDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil.
Airlane Pereira AlencarDepartment of Statistics, State University of São Paulo, São Paulo, SP 05508-900, Brazil.
Vladimir Costa SilvaDepartment of Molecular Biology, Natan Portella Hospital, Federal University of Piaui, Teresina, PI 64001-450, Brazil.
Benedito Borges Da SilvaDepartment of Gynecology, Federal University of Piauí, Health Sciences Center, Teresina, PI 64001-020, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present, there is controversy regarding the efficacy of tamoxifen in breast cancer patients who are carriers of cytochrome P450 2D6 (CYP2D6) gene polymorphisms, in terms of recurrence and overall survival. Thus, the aim of the present study was to investigate the association of the CYP2D6 *4, *10 and *17 gene polymorphisms with breast cancer recurrence in a Brazilian population. The cohort comprised 40 receptor-positive breast cancer patients without recurrence and 40 with distant recurrence. A 3-ml sample of peripheral blood was collected from each patient to determine the presence of the *4, *10 and *17 single nucleotide polymorphisms of the CYP2D6 gene by quantitative polymerase chain reaction analysis. There was no statistically significant difference between the two groups regarding the polymorphism frequency (P=0.246). The results revealed that intermediate metabolizers occurred in 5% of patients without recurrence and in 15% of those with distant recurrence. Poor metabolizers occurred in only 1 patient (2.5%) per group, and there was no significant difference between the groups (P=0.789). The present study concluded that the CYP2D6 gene polymorphism in women with hormone-sensitive breast cancer treated with tamoxifen was not associated with disease recurrence.

Indexed as

breast cancercytochrome P450 2D6 genepolymorphismrecurrencetamoxifen

Identifiers

PMID27882219
PMCPMC5103674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.